The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index; 14 of the 34 sources its claims cite were checked for support.
RETATRUTIDE USE IN THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND OBESITY: AN INTEGRATIVE REVIEW
Open accessAbstract
Obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) are major global public health challenges, being associated with increased morbidity, mortality, and healthcare costs. In this context, novel pharmacological therapies have been developed to promote significant weight reduction and improve metabolic and hepatic outcomes. Retatrutide, a triple agonist of the GLP-1, GIP, and glucagon receptors, has emerged as an innovative therapeutic approach due to its ability to simultaneously target multiple pathways involved in energy metabolism regulation. The aim of this study was to analyze the available scientific evidence regarding the use of retatrutide in the treatment of obesity and MASLD. This integrative literature review included studies published between 2016 and 2026, identified through searches in the MEDLINE/PubMed and ScienceDirect databases. Clinical trials, prospective studies, systematic reviews, and relevant publications addressing the topic were included. The analyzed evidence demonstrated that retatrutide promotes weight reductions exceeding 24%, in addition to significant improvements in metabolic, glycemic, and cardiovascular parameters. In patients with MASLD, substantial reductions in liver fat content, exceeding 80% at higher doses, were observed, along with high rates of normalization of hepatic fat levels. Compared with previously established incretin-based therapies, such as semaglutide and tirzepatide, retatrutide showed particularly promising results. In conclusion, retatrutide represents one of the most innovative pharmacological approaches currently under development for the treatment of obesity and MASLD, although long-term studies are still required to confirm its sustained efficacy and clinical safety.
Overview
CoChat Summary
TL;DR
This integrative review argues that retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, is highly effective for obesity and shows promising reductions in hepatic fat in MASLD. The paper concludes that results are strong but long-term studies are still needed to confirm sustained efficacy, safety, and effects on harder clinical outcomes.
Key findings
- In a randomized clinical trial of people with obesity or overweight plus comorbidities, 48 weeks of retatrutide produced mean weight reductions of 22.8% at 8 mg and 24.2% at 12 mg, with a clear dose-response relationship.
- The paper reports that in MASLD, retatrutide led to hepatic fat reductions exceeding 80% at the highest doses evaluated after 24 weeks, with high rates of normalization of hepatic fat levels.
- Compared with prior incretin therapies, the review states semaglutide achieved about 14.9% mean weight loss and tirzepatide up to 20.9%, while retatrutide showed greater weight loss, “exceeding 24%.”
- The review says retatrutide also improved waist circumference, glycaemia, glycated haemoglobin, blood pressure, and other cardiometabolic parameters.
Methods
- Integrative literature review of retatrutide for obesity and MASLD.
- Searches were conducted in PubMed/MEDLINE and ScienceDirect for publications from January 2016 to June 2026; included English-language clinical trials, prospective studies, observational studies, and systematic reviews, plus relevant articles.
- The final sample comprised nine publications; analysis was descriptive, comparative, and narrative, organizing findings into themes on mechanism of action, weight loss, hepatic fat reduction, and future perspectives.
Limitations
- The paper states that most available data derive from phase 2 studies with relatively short follow-up periods, limiting conclusions about durability of benefit.
- It says evidence remains limited for fibrosis regression, prevention of cirrhosis, long-term hepatic complications, prolonged safety, therapeutic adherence, and cost-effectiveness.
- Evident from the text: the review is based on nine publications and uses a narrative synthesis, so its conclusions depend on a small, heterogeneous evidence base rather than pooled quantitative analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 1 Not valid · 15 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In patients with MASLD, substantial reductions in liver fat content, exceeding 80% at higher doses, were observed, along with high rates of normalization of hepatic fat levels.”
- Also stated in: § 1 INTRODUCTION · plain
“In patients with metabolic dysfunction-associated steatotic liver disease, treatment was associated with expressive reductions in hepatic fat, with decreases exceeding 80% at some evaluated doses”
- Also stated in: § 3.2 EFFICACY OF RETATRUTIDE IN THE TREATMENT OF OBESITY · boosted
“The most relevant results on the use of retatrutide in patients with MASLD demonstrated expressive reductions in hepatic fat, exceeding 80% at the highest doses evaluated after 24 weeks of treatment.”
What the sources say
- Supportedcites SANYAL et al., 2024 source
The Results section (“Changes in hepatic fat fraction”; page not available) reports mean relative liver-fat reductions of 81.4% and 82.4% after 24 weeks at the 8 mg and 12 mg doses. It also reports that 79% and 86% of participants in those groups, respectively, reached liver-fat content below 5%, supporting the citing sentence’s description of high normalization rates. (LLM, conf=0.95)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 1 INTRODUCTION · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“as well as high rates of normalisation of hepatic lipid content”
- Also stated in: § 3.2 EFFICACY OF RETATRUTIDE IN THE TREATMENT OF OBESITY · hedged
“a significant proportion of participants reached levels considered normal for hepatic fat, suggesting an important regression of steatosis”
What the sources say
- Supportedcites SANYAL et al., 2024 source
The Discussion reports that more than 85% of participants with MASLD at the two highest retatrutide doses achieved resolution of steatosis, defined as less than 5% total liver fat content. This supports the cited description of high rates of normalization of hepatic fat content. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 3.2 EFFICACY OF RETATRUTIDE IN THE TREATMENT OF OBESITY · hedged
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Clinical evidence demonstrated that the combination of these two pathways promotes benefits superior to those observed with isolated GLP-1 agonists, a fact initially evidenced by the results obtained with tirzepatide in the treatment of obesity”
What the sources say
- Could not verifycites WILDING et al., 2021 sourceExperimental — accuracy not yet measured
The Discussion compares weight loss with semaglutide and liraglutide, both GLP-1 receptor agonists. Our copy does not address combined GLP-1 and GIP activity or tirzepatide, so it cannot verify the claimed superiority of the combined pathways (searched: tirzepatide, GIP, and dual GLP-1/GIP agonism). (LLM, conf=0.76)
- Not checked — no full text of the sourcecites JASTREBOFF et al., 2022 source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Most of the available data derive from phase 2 studies, with relatively short follow-up periods when compared with the chronic nature of obesity and metabolic dysfunctionassociated steatotic liver disease.”
What the sources say
- Not checked — no full text of the sourcecites JASTREBOFF et al., 2023 source
- Partly supportedcites SANYAL et al., 2024 sourceExperimental — accuracy not yet measured
The Methods (Study design and participants; page unavailable) describe this as a 48-week phase 2 trial, and the Discussion calls its results hypothesis-generating rather than definitive. These passages support the point that the cited retatrutide data have limited follow-up, but the paper does not establish that most available retatrutide data come from phase 2 studies. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although current studies demonstrate expressive reductions in hepatic fat, the evidence related to the regression of fibrosis, prevention of cirrhosis, and reduction of long-term hepatic complications remains limited.”
What the sources say
- Partly supportedcites ABOUELMAGD et al., 2025 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports a significant reduction in liver fat and says further trials are needed to determine retatrutide’s long-term clinical outcomes. Its limitations section also notes a lack of long-term data, but the paper does not specifically address evidence on fibrosis regression or cirrhosis prevention. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
13 more claims · 2 with their cited sources checked
Create a free account to see all 32 claims and every source verdict.
- It may state two separate claims as one. 11
- Probably not a substantial claim. 3
- The quote only partly states this claim. 1
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Metadata
- Authors
- Santos, G. V. D., Nascimento, E. D. S. R. D., Carvalho, R. O. V., Teixeira, M. S., Bezerra, P. T. M., Vieira, L. H. S., Bezerra, I. P., Salvadego, M. A. L. D. O., Alexandre, B. G. F., Nascimento, S. B. D., Nascimento, S. L. D. O. R., Moura, M., Bastos, F. D. O., Siqueira, A. L. D., Machado, F. M., Silva, I. P. E., Oliveira, A. C. G. D., Beltrão, C. A. M. D. S., Amestoy, H. B., Almeida, R. K. D., Grando, V. G., Neves, T. D. A., Neri, D. N., & Reis, T. D. S. O.
- Affiliations
- Universidade Federal de Santa Maria (BR)
- Universidad María Auxiliadora (PE)
- Universidade Luterana do Brasil (BR)
- Universidade Federal de Goiás (BR)
- Universidade Regional do Noroeste do Estado do Rio Grande do Sul (BR)
- Universidade do Oeste Paulista (BR)
- Universidade Evangelica de Goiás (BR)
- Centro Universitário Fundação Assis Gurgacz (BR)
- Universidade Federal do Pará (BR)
- ORCID
- Bezerra, Iza Pereira
- Venue
- Pathways to Health: Innovations and Approaches in Health Sciences - 2nd Edition
- Publisher
- Seven Editora
- Published
- 2026-07-09
- OpenAlex
- W7167834509
- Cited by
- 0
- References
- 0
- FWCI
- 0.00
- Type
- book chapter
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Seven Editora eBooks (publishedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- retatrutide, non-alcoholic fatty liver disease, obesity, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist, weight loss, hepatic steatosis, liver fat reduction, semaglutide, tirzepatide, incretin-based therapy, glycemic control, cardiovascular outcomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RETATRUTIDE USE IN THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND OBESITY: AN INTEGRATIVE REVIEW. https://app.cochat.ai/papers/10.56238/sevened2026.020-072
- The paper
- Santos, G. V. D., Nascimento, E. D. S. R. D., Carvalho, R. O. V., Teixeira, M. S., Bezerra, P. T. M., Vieira, L. H. S., Bezerra, I. P., Salvadego, M. A. L. D. O., Alexandre, B. G. F., Nascimento, S. B. D., Nascimento, S. L. D. O. R., Moura, M., Bastos, F. D. O., Siqueira, A. L. D., Machado, F. M., Silva, I. P. E., Oliveira, A. C. G. D., Beltrão, C. A. M. D. S., Amestoy, H. B., . . . Reis, T. D. S. O. (2026). RETATRUTIDE USE IN THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND OBESITY: AN INTEGRATIVE REVIEW. Pathways to Health: Innovations and Approaches in Health Sciences - 2nd Edition. https://doi.org/10.56238/sevened2026.020-072
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.